The National Institute for Health Care Management (NIHCM) Foundation is a nonprofit, nonpartisan organization dedicated to improving the health of all Americans by spurring workable and creative solutions to pressing healthcare problems.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
Initial safety and efficacy findings from this first-in-human series “look really impressive,” but experts await further studies.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
As demand for the drug continues to rise, alternatives like the oral formulation and other injectable GLP-1s come into play.
The first-in-human results represent “an encouraging first step with a novel ablation source,” one expert says.
Findings from a Finnish study don’t reveal a reason for the trend, but some speculate it could be due to better risk factor control.
The hope is that this will make ablation safer and increase the number of patients considered candidates, Stylianos Tzeis says.
There could be confounders related to socioeconomic status at play, one expert says.
The Farapulse system provides US physicians with another PFA option for the treatment of paroxysmal AF.
Findings like these suggest that earlier treatment with CRT may be warranted, Lynne Warner Stevenson says.
